group (DM group), ICA II treatment group (DM + ICA II group). Western blot to detect the expression of eNOS, RAGE protein expression so as to make sure the success of model construction; immunofluorescence assay to study the proliferation of (HCECs); real time PCR to detect the expression of miR-126 and Spred1; western blot to detect the expression of the Spred1/c-Raf/MEK1/2/Erk1/2. Tube Formation Assay and Scratch assay were performed to detect the angiogenesis of HCECs under the diabetic-like environment.
group (DM group), ICA II treatment group (DM + ICA II group). Western blot to detect the expression of eNOS, RAGE protein expression so as to make sure the success of model construction; immunofluorescence assay to study the proliferation of (HCECs); real time PCR to detect the expression of miR-126 and Spred1; western blot to detect the expression of the Spred1/c-Raf/MEK1/2/Erk1/2. Tube Formation Assay and Scratch assay were performed to detect the angiogenesis of HCECs under the diabetic-like environment.
Results: Under the model, the expression of eNOS in DM group significantly reduced compared with that of NC group and the expression of RAGE in DM group is significantly increased compared with that of NC group (P<0.05), but the DM + ICA II group showed higher eNOS expression and lower RAGE expression compared with those in the DM group. The Ki67 expression in DM group is lowered than that in NC group; whereas the Ki67 expression in DM + ICA II group is higher when compared with that in DM group. The expression of miR-126 in DM group is significantly reduced compared with that of NC group but the DM + ICA II group showed higher miR-126 expression compared with that in the DM group. Western blot results showed Spred1 expression increased under the diabetic condition and its downstream target genes c-Raf/ MEK1/2/Erk1/2 expression decreased obviously, but ICA II adding into the DM group could reverse these results effectively. Tube Formation Assay and Scratch assay also showed ICA II could promote the tube formation and cell proliferation in impairment of endothelial dysfunction of DM group. Conclusions: Under the simulation of Age-BSA and glucose, HCECs occurred the endothelial dysfunction and the angiogenesis were repressed; ICA II could restore the HCECs functions by miR-126/Spred1/c-Raf/MEK1/2/ Erk1/2 pathway. ICA II may be a promising therapeutic compound to treat endothelial dysfunction in the future. Background: To investigate the role of Icariside II (ICA II) on endothelial nitric oxide synthase (eNOS) expression regulated by miR-155, the human cavernous endothelial cells (HCECs) were exposed to a diabetic-like environment and treated with ICA II. Methods: HCECs were treated with 200 μg/mL BSA as the Normal Control group (NC), with 200 μg/mL AGE-BSA plus 250 mg/dL glucose as the diabetes mellitus (DM) group, or with an addition of ICA II in DM group as the treatment group (DM+ICA II). Bioinformatics were first used to predict miRNAs targeting eNOS gene and then potential candidates including miR-155, miR-543, miR-31, miR-429, miR-200b were further verified by real-time PCR in a diabetic-like condition. Expressions levels of miRNAs, eNOS and the receptor for advanced glycation end products (RAGE) were performed by Real-time PCR; Protein expression levels of eNOS and RAGE were analyzed by western blot; nitric oxide (NO) content was detected by DAF-FM DA probe and NaNO 2 standard curve methods. Results: The expression of miR-155 in DM group is significantly higher than that that in the normal control (NC) group, whereas this phenomenon was effectively reversed by ICA II treatment. Furthermore, the miR-155 targeting gene eNOS and its consequent NO product were significantly reduced in DM group, while these changes were also recovered after ICA II treatment.
Conclusions:
In this study, we demonstrated that ICA II could promotes eNOS mRNA and protein levels by suppressing miR-155 in HCECs exposed to a diabetic-like environment. Background: This study aimed to explore the therapeutic effects of adipose-derived stem cells (ADSCs)-based microtissues (MTs) on erectile dysfunction (ED) in streptozotocin (STZ) induced diabetic rats. Methods: Fifty-six 8-week-old Sprague-Dawley rats received intraperitoneal injection of STZ (60 mg/kg) and eight weeks later, the determined diabetic rats randomly got intracavernous (IC) injection of phosphate buffer solution (PBS), ADSCs or MTs. Another eight normal rats equally received IC injection of PBS. MTs were generated with a hanging drop method and the injected cells were tracked in ADSCs and MTs injected rats. Four weeks after the treatments, intracavernous pressure (ICP), histopathological changes in corpus cavernosum (CC), and functional proteins were measured. Rat cytokine antibody array was used to detect ADSCs or MTs lysate. Results: MTs expressed vascular endothelial growth factor (VEGF), nerve growth factor (NGF) and tumor necrosis factor-stimulated gene 6 (TSG-6). MTs injection had a higher retention than ADSCs injection and MTs treatment better improved ICP, neuronal nitric oxide synthase (nNOS) expression, smooth muscle and endothelial contents in diabetic rats, ameliorated local inflammation in CC. Conclusions: IC injection of MTs improves the erectile function and histopathological changes in streptozotocininduced diabetic rats and appears to be more promising than traditional ADSCs. The underlying mechanisms involve increased cell retention accompanied with neuroprotection and anti-inflammatory behaviors of the paracrine factors. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
510080, China
Background: Although cancers are widely considered to be maintained by stem cells, the existence of stem cells in renal cell carcinoma (RCC) has seldom been reported, in part due to the lack of unique surface markers. 
